Strengthening research, technological development and innovation
Promoting innovation capacities for a more competitive area
New Immuno-Cluster. Pilot project to improve quality and life expectancy of women with Triple Negative Breast Carcinoma (TNBC) focused on HybriCure® immunoibridioma (Celica), bioreactors (VivaBioCell, NANT) for automated production, innivative SMEs , hospitals / Lead User. Immuno-Cluster creates a system of common resources (qualified personnel, know-how) among project partners and local private and public actors for TNBC therapy improving the quality and life expectancy of women in the area (at the moment, there are no satisfactory treatments).
The purpose of the Immuno-Cluster project was to establish cross-border cooperation through clinical research for the treatment of triple-negative breast cancer using an autologous cell vaccine (immunohybridomas), which was introduced years ago by the leading partner (Celica Biomedical). In this project, in addition to the preparation of a protocol for a new clinical study, there was also an increase in production in "closed" bioreactors. For this purpose, the validation of the preparation of dendritic cells on the so-called "open" mode (Celica Biomedical) and on the so-called "closed" method of production with an automatic bioreactor (VivaBioCell). The results of the measurements showed the consistency of the two methodologies and the success of the validation of the two technologies created greater access to the treatment of patients in the region through the introduction of transregional clinical studies. The project thus made it possible to perfectly connect top hospitals with pharmaceutical and biotechnology companies, universities and research centers that operate at the highest European and global level. As part of the project, the activities and results of the project were also disseminated outside the program area, namely at EXPO 2020, which took place in Dubai in January 2022 (due to the pandemic), where a new method of treating solid cancers was presented for the first time. on an international level.
The main goal of the project was the preparation of a joint clinical protocol for triple-negative breast cancer with the cross-border contribution of three clinics and the approval of local ethics committees from Slovenia and Italy. By achieving this goal, together with the production scale-up and validation of two dendritic cell preparation technologies, a foundation has been created for future good practice for transnational clinical research in the region in the future. This was only possible through cooperation and through the upgrading of the exchange of expertise of various partners on a transnational level, where research institutions, clinics and companies working in the field of regenerative medicine and biomedical research into the introduction of cellular medicines for advanced treatment participated. The international public was informed about the results of this project through a high-profile presentation in the pavilion of the Republic of Slovenia in January 2022 at EXPO 2020, Dubai.
Lead Partner
Project partner 1
Project partner 2
Project partner 3
Project partner 4
Project partner 5
KEY PROJECT OBJECTIVES
The main goal of the project was the preparation of a joint clinical protocol for triple-negative breast cancer with the cross-border contribution of three clinics and the approval of local ethics committees from Slovenia and Italy. By achieving this goal, together with the production scale-up and validation of two dendritic cell preparation technologies, a foundation has been created for future good practice for transnational clinical research in the region in the future. This was only possible through cooperation and through the upgrading of the exchange of expertise of various partners on a transnational level, where research institutions, clinics and companies working in the field of regenerative medicine and biomedical research into the introduction of cellular medicines for advanced treatment participated. The international public was informed about the results of this project through a high-profile presentation in the pavilion of the Republic of Slovenia in January 2022 at EXPO 2020, Dubai.
STATUS OF IMPLEMENTATION OF THE PROJECT: The project is completed. It started on 1/1/2020 and was extended for 6 months due to the pandemic with a formal conclusion on 30/6/2022.
Operation co-funded by the European Regional Development Fund
